BMS and Merck Race to Melanoma Treatment Market
Merck’s Keytruda, recently approved in the US to treat patients with advanced melanoma that have stopped responding to other cancer therapies, will soon face strong competition from Bristol-Myers Squibb’s (BMS) Opdivo, an analyst from research and consulting firm GlobalData has reported.
Merck’s Keytruda, recently approved in the US to treat patients with advanced melanoma that have stopped responding to other cancer therapies, will soon face strong competition from Bristol-Myers Squibb’s (BMS) Opdivo, an analyst from research and consulting firm GlobalData has reported.
Keytruda is the US’s first-to-market therapy that targets the programmed cell death receptor-1 (PD-1), better enabling the immune system to fight cancer. However, according to GlobalData’s Fenix Leung, BMS’s Opdivo could receive approval from the European Medicines Agency for first-line melanoma treatment as early as Q2 2015.
Leung added that BMS is clearly working on a tight deadline to push Opdivo ahead of Keytruda in the EU.
Opdivo’s Phase III CheckMate-067 trial included an investigation of a Yervoy/Opdivo combination, which showed unmatched efficacy in a Phase 1b trial. The median overall survival of patients was 40 months, more than double that of either drug alone.
Leung commented: “Combination strategies are essential in the race to capture a large share of one of the most promising markets in cancer immunotherapy… Nonetheless, we will need to wait for the safety results from the CheckMate-067 trial, due in the fall of 2016, to gain an improved understanding of the Yervoy/Opdivo combination’s safety profile prior to approval in either the US or EU.”
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
